Testing a new drug for early Parkinson's disease
Part of Brain & nervous system clinical trials.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 85 years old.
- You have been diagnosed with Parkinson's disease (not caused by another condition).
- You have been taking a stable dose of levodopa for at least 2 months.
- You do not have dementia or other significant neurological conditions.
- You do not have unstable heart disease or poorly controlled high blood pressure.
- You are able to swallow capsules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment (LY3962681) for people with early Parkinson's. It aims to see if the treatment is safe and can slow the disease. You must have a confirmed diagnosis, be in good overall health, and have stable medication use.
This trial tests an experimental drug called MT101-5 for people recently diagnosed with Parkinson's disease. It aims to see if the drug is safe and can help control symptoms.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.